Pesquisar
Spero Therapeutics Inc
SPROAdicionar à lista de desejos
2.200USD
-0.020-0.90%
Fechamento 07/02, 13:00（ET）Cotações atrasadas em 15 min
127.38MValor de mercado
7.92P/L TTM
Mais detalhes de Spero Therapeutics Inc Empresa
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying and developing novel treatments for rare diseases and diseases caused by multi-drug resistant (MDR) bacterial infections with unmet need. Its product candidate SPR720 is an investigational, chemically stable phosphate ester prodrug that is converted in vivo to SPR719 for the treatment of nontuberculous mycobacterial (NTM) pulmonary disease. Its clinical stage product candidate, tebipenem HBr is an investigational oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections (cUTIs) including acute pyelonephritis (AP) to help patients potentially reduce duration of in-patient therapy.
Informações de Spero Therapeutics Inc
Código da empresaSPRO
Nome da EmpresaSpero Therapeutics Inc
Data de listagemNov 02, 2017
CEORajavelu (Esther)
Número de funcionários32
Tipo de títulosOrdinary Share
Fim do ano fiscalNov 02
Endereço675 Massachusetts Ave Ste 14
CidadeCAMBRIDGE
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal02139-3309
Telefone18572421600
Sitehttps://sperotherapeutics.com/
Código da empresaSPRO
Data de listagemNov 02, 2017
CEORajavelu (Esther)
Executivos da empresa Spero Therapeutics Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Ankit Mahadevia, M.D.
Dr. Ankit Mahadevia, M.D.
Non-Executive Director
Non-Executive Director
364.22K
-1.80%
Mr. Timothy (Tim) Keutzer
Mr. Timothy (Tim) Keutzer
Chief Operating Officer
Chief Operating Officer
335.13K
+55.82%
Ms. Esther Rajavelu
Ms. Esther Rajavelu
President, Chief Executive Officer, Chief Financial Officer, Treasurer and Chief Business Officer
President, Chief Executive Officer, Chief Financial Officer, Treasurer and Chief Business Officer
229.84K
-10.98%
Dr. Milind S. Deshpande, Ph.D.
Dr. Milind S. Deshpande, Ph.D.
Independent Director
Independent Director
71.45K
-27.99%
Mr. Frank E. Thomas, CPA
Mr. Frank E. Thomas, CPA
Independent Chairman of the Board
Independent Chairman of the Board
55.00K
-36.36%
Ms. Cynthia Smith
Ms. Cynthia Smith
Independent Director
Independent Director
55.00K
-36.36%
Ms. Kathleen Tregoning
Ms. Kathleen Tregoning
Independent Director
Independent Director
55.00K
-36.36%
Dr. Patrick Volkert Jozef Johannes Vink, M.D.
Dr. Patrick Volkert Jozef Johannes Vink, M.D.
Lead Independent Director
Lead Independent Director
--
--
Dr. John C. Pottage, Jr., M.D.
Dr. John C. Pottage, Jr., M.D.
Independent Director
Independent Director
--
--
Mr. Scott T. Jackson
Mr. Scott T. Jackson
Independent Director
Independent Director
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Ankit Mahadevia, M.D.
Dr. Ankit Mahadevia, M.D.
Non-Executive Director
Non-Executive Director
364.22K
-1.80%
Mr. Timothy (Tim) Keutzer
Mr. Timothy (Tim) Keutzer
Chief Operating Officer
Chief Operating Officer
335.13K
+55.82%
Ms. Esther Rajavelu
Ms. Esther Rajavelu
President, Chief Executive Officer, Chief Financial Officer, Treasurer and Chief Business Officer
President, Chief Executive Officer, Chief Financial Officer, Treasurer and Chief Business Officer
229.84K
-10.98%
Dr. Milind S. Deshpande, Ph.D.
Dr. Milind S. Deshpande, Ph.D.
Independent Director
Independent Director
71.45K
-27.99%
Mr. Frank E. Thomas, CPA
Mr. Frank E. Thomas, CPA
Independent Chairman of the Board
Independent Chairman of the Board
55.00K
-36.36%
Ms. Cynthia Smith
Ms. Cynthia Smith
Independent Director
Independent Director
55.00K
-36.36%
Perguntas frequentes
Quem são os cinco principais acionistas de Spero Therapeutics Inc?
Os cinco principais acionistas de Spero Therapeutics Inc são: Dr. Ankit Mahadevia, M.D.
Quantas instituições possuem ações da Spero Therapeutics Inc (SPRO)?
Em 2026Q1, 117 instituições possuíam ações da Spero Therapeutics Inc, com valor de mercado aproximado de 11.81M, representando 20.40% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em -1291189.00.
Qual é a maior fonte de receita da Spero Therapeutics Inc?
Em 2026Q1, o segmento de negócios Collaboration Revenue Related Party gerou a maior receita para Spero Therapeutics Inc, totalizando 47.03M e representando 70.41% da receita total.